Novartis oral Fabhalta ® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial By Investing.com
New APPEAR-C3G knowledge present Fabhalta sustained proteinuria discount at 12 months1Upon Fabhalta initiation, enchancment noticed in estimated glomerular filtration price ...